NewAmsterdam Pharma Company NV. (NAMS) NASDAQ
$21.35 (0.46) (-2.09%)
Market Cap: $1.95B
As of 04/25/24 01:52 PM EDT. Market open.
NewAmsterdam Pharma Company NV. (NAMS)
NASDAQ
$21.35
(0.46) (-2.09%)
Market Cap: $1.95B
As of 04/25/24 01:52 PM EDT. Market open.
Add to Portfolio
... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
PRICE CHART FOR NEWAMSTERDAM PHARMA COMPANY NV
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$21.51
Previous Close
$21.80
Days Range
$21.48 - $22.10
52 week range
$5.63 - $26.35
Volume
40,583
Avg. Volume (30 days)
236,612
Market Cap
$1.95B
Dividend Yield
-
P/E
-
Shares Outstanding
89,266,673
Open
$21.51
Previous Close
$21.80
Days Range
$21.48 - $22.10
52 week range
$5.63 - $26.35
Volume
40,583
Avg. Volume (30 days)
236,612
Market Cap
$1.95B
Dividend Yield
-
P/E
-
Shares Outstanding
89,266,673
FINANCIAL STATEMENTS FOR NEWAMSTERDAM PHARMA COMPANY NV
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR NEWAMSTERDAM PHARMA COMPANY NV
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Topper James N | Director | Mar 26, 2024 | Buy | $21.50 | 8,429 | 181,224 | 3,008,429 | Mar 28, 2024, 04:30 PM |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 26, 2024 | Option Exercise | $22.72 | 11,197 | 254,396 | 190,476 | Mar 27, 2024, 04:30 PM |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 26, 2024 | Sale | $21.50 | 190,476 | 4,095,234 | 0 | Mar 27, 2024, 04:30 PM |
| LANGE LOUIS G | Director | Feb 13, 2024 | Buy | $19.00 | 5,000 | 95,000 | 24,878 | Feb 21, 2024, 05:00 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Topper James N | Director | 03/26/2024 | 181,224 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 03/26/2024 | 254,396 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 03/26/2024 | 4,095,234 |
| LANGE LOUIS G | Director | 02/13/2024 | 95,000 |
FUNDS WITH A POSITION IN NEWAMSTERDAM PHARMA COMPANY NV
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 8,024,565 | 0.33% | No change | Growth At A Reasonable Price |
| RA CAPITAL MANAGEMENT, L.P. | 7,864,000 | 1.37% | -12.62% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,300,000 | 0.03% | 8.33% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 47,324 | 0.00006% | 13.19% | Other |
| BLACKROCK INC. | 22,941 | 0.00001% | No change | Other |
| DUPONT CAPITAL MANAGEMENT CORP | 1 | 0% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR NEWAMSTERDAM PHARMA COMPANY NV
STOCK BUYBACKS FOR NEWAMSTERDAM PHARMA COMPANY NV
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
06/30/2023
19.36%
2Q
12/31/2022
25.32%
4Q
BUYBACK ANNOUNCEMENT(S) FOR NEWAMSTERDAM PHARMA COMPANY NV
LOADING...